ArticleJournal of pediatric gastroenterology and nutrition2026
Impact of 5-Aminosalicylic acid discontinuation in children with ulcerative colitis on biologic therapy: A propensity score-matched study.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of 5-Aminosalicylic acid discontinuation in children with ulcerative colitis on biologic therapy: A propensity score-matched study.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectives5-Aminosalicylic acid (5-ASA) is recommended as a first-line medication in mild to moderate ulcerative colitis (UC), but indications regarding its use in children with moderate to severe disease treated with biologics are lacking. We aimed to evaluate the impact of discontinuing 5-ASA in children with UC treated with anti-tumor necrosis factor (anti-TNF).
methodsRetrospective, multicenter, case-control study of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition inflammatory bowel disease (IBD) study group. Children with UC starting anti-TNF therapy between January 2018 and January 2023 and with a minimum follow of 6 months were included. Those who discontinued 5-ASA (cases) were compared to those who continued mesalamine (controls). A Propensity Score analysis was used to match 1:2 with patients by baseline clinical and demographic characteristics. Every 6 months, during a 2-year follow-up, data on disease flares, IBD-related hospitalization, surgery, need for step-up treatment and acute severe colitis were recorded.
resultsData from 298 children were collected (92 [31%] cases and 206 [69%] controls) and 227 were included in the final analysis after matching (85 [37.5%] cases and 142 [62.5%] controls]. Children who discontinued 5-ASA were at higher risk of courses of steroids (Log-Rank p = 0.003) and hospitalization (p = 0.08). At the multivariate Cox regression analysis, 5-ASA discontinuation was identified as an independent predictor of courses of steroids (p = 0.003) and hospitalization (p = 0.08).
conclusions5-ASA discontinuation might negatively impact the clinical course of children with UC treated with anti-TNF. Considering the good safety profile of the drug, continuing mesalamine can be suggested as a prudent approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.